poisar

Stocks · News reference

Calidi Biotherapeutics Announces Registered Direct Offering 1,025,640 Shares At $1.17 Per Share

Benzinga Newsdesk

The closing of the registered direct offering is expected to occur on or about September 18, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Calidi from the registered direct

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CLDI
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency

    Calidi Biotherapeutics received a notice from NYSE American on September 21, 2026, indicating non-compliance with continued listing standards due to stockholders' equity deficiency of less than $4.0 million. The company has until October 21, 2026, to submit a compliance plan and must regain compliance by March 21, 2028, or face delisting proceedings. The company's stock will trade with a '.BC' designation indicating below-compliance status, though trading continues unaffected.

    CLDI